Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients With Radiographic Axial Spondyloarthritis

Next Previous
Trial Profile

A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients With Radiographic Axial Spondyloarthritis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ixekizumab (Primary) ; Adalimumab
  • Indications Ankylosing spondylitis; Axial spondyloarthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms COAST-V
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 15 Nov 2023 Results of post hoc analysis (N=81) assessing the association between treatment response at Week (W)12 and W24, and attainment of the ASDAS < 2.1 treat to target recommendation at W52 in patients with radiographic axSpA treated with ixekizumab presented at the ACR Convergence 2023
  • 15 Nov 2023 Post-hoc results assessing post-hoc analyses of patients with MRI available at baseline and week 16 for placebo, Ixekizumab Q2W, Ixekizumab Q4W and adalimumab groups were presented at the ACR Convergence 2023.
  • 03 Jun 2023 Post-hoc results (n=587) from COAST-V, COAST-X, COAST-W studies presented at the 24th Annual Congress of the European League Against Rheumatism.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top